Researchers at Wadhwani School of Data Science and AI (WSAI) and ICMR-National Institute for Research in Reproductive and ...

High responses maintained over four years in nearly half of patients: 48.9% of Week 16 PASI 0 responders sustained complete ski ...

UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa (HS).